No Data
Humacyte Price Target Maintained With a $15.00/Share by Benchmark
Humacyte Price Target Maintained With a $15.00/Share by Benchmark
Cantor Fitzgerald Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $7
Cantor Fitzgerald analyst Kristen Kluska maintains $Humacyte(HUMA.US)$ with a buy rating, and adjusts the target price from $6 to $7.According to TipRanks data, the analyst has a success rate of 37.0%
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Benchmark analyst Bruce Jackson reiterates Humacyte with a Buy and maintains $15 price target.
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 160.87% Benchmark $15 → $15 Reiterates Buy → Buy 05/24/2024 160.87% Benchmark $15 → $15 Reitera
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
Benchmark Co. analyst Bruce Jackson maintains $Humacyte(HUMA.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 28.9% and a tot
While Institutions Own 20% of Humacyte, Inc. (NASDAQ:HUMA), Individual Investors Are Its Largest Shareholders With 50% Ownership